{"filings":[{"id":2189524,"accession_number":"0001672688-26-000134","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-08-11T20:06:14+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci reports positive interim Phase 1 data for ABS-201; completes $100M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Positive interim Phase 1 data for ABS-201: well tolerated, half-life ≥65 days, supports 2-3 doses/6 months.","Completed $100M underwritten offering incl. $40M strategic investment from Eli Lilly; net proceeds $93.6M.","Cash and securities $201.1M at 6/30/26, up from $125.7M at 3/31/26; runway into H2 2028.","Q2 2026: revenue $0.3M (vs $0.6M YoY); net loss $33.2M (vs $30.6M YoY).","ABS-201 endometriosis Phase 2 planned Q4 2026; PHL proof-of-concept data H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":"2026-08-11","daily_digest_url":"/daily/2026-08-11","daily_digest_rank":6},{"id":1250396,"accession_number":"0001193125-26-281143","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-06-24T20:31:58+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Absci prices $100M common stock offering at $7.41/share; Lilly, other investors participate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["13,495,277 shares priced at $7.41 each; gross proceeds ~$100M, net ~$93.5M after fees.","Offering includes participation from Eli Lilly, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile.","Net proceeds to fund AI-designed anti-PRLR antibody ABS-201 for alopecia and endometriosis.","Offering expected to close June 25, 2026; Jefferies, J.P. Morgan, TD Cowen, Guggenheim as bookrunners.","Shares sold under effective shelf registration statement (File No. 333-289541)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1231116,"accession_number":"0001672688-26-000118","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-06-24T10:32:11+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci reports positive interim Phase 1 data for ABS-201; half-life ≥65 days supports dosing 2-3 times/6 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No serious adverse events; TEAEs were mild except one moderate headache deemed unrelated to treatment.","Estimated half-life of at least 65 days across all four SAD cohorts (150–1800 mg IV).","MAD portion in androgenetic alopecia participants initiated; interim PoC data expected H2 2026.","Phase 2 trial for endometriosis planned later this year.","32 healthy volunteers enrolled in four SAD cohorts; data cutoff June 8, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":888318,"accession_number":"0001672688-26-000095","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-06-05T20:08:47+00:00","items":["5.07"],"status":"ready","headline":"Absci shareholders elect two Class II directors, ratify E&Y as auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II director Pangalos elected with 74,118,258 for, 9,332,380 withheld, 29,904,399 broker non-votes.","Class II director Rabinovitsj elected with 69,590,534 for, 13,860,104 withheld, 29,904,399 broker non-votes.","Ratification of Ernst & Young as independent auditor passed: 111,058,992 for, 2,198,390 against, 97,655 abstain.","Annual meeting held June 4, 2026; record date April 7, 2026 with 155,447,428 shares outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94572,"accession_number":"0001672688-26-000086","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.","Initiated MAD dosing in AGA participants; preliminary PK supports 2-3 injections over six months.","Expanded pipeline with ABS-202, a novel anti-PRLR antibody for undisclosed I&I indication.","Q1 revenue $0.2M, net loss $29.6M; cash $125.7M sufficient into first half of 2028.","Anticipates reporting preliminary safety, tolerability, PK data in Q2 2026; proof-of-concept in H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":215000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107056,"accession_number":"0001672688-26-000066","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-03-24T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.","Net loss Q4 2025 $29.6M vs $29.0M prior year; full year net loss $115.2M vs $103.1M.","Cash, equivalents, and marketable securities $144.3M as of Dec 31, 2025; sufficient to fund operations into first half 2028.","Appointed Ransi Somaratne, M.D. (former Vertex SVP) as Chief Medical Officer to lead clinical strategy.","Interim proof-of-concept data for ABS-201 expected H2 2026; Phase 2 endometriosis trial initiation planned Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107055,"accession_number":"0001672688-26-000047","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-03-06T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.","Andreas Busch, Chief Innovation Officer, will retire March 31, 2026 and serve as scientific advisor for 2 years.","Busch receives $25,500 annual retainer plus grants of 22,800 stock options and 5,800 RSUs under the 2021 Plan.","Busch's vested options (2,489,290 shares) extended up to 3 months post-advisory termination; unvested options cancelled.","Amended director and officer indemnification agreements adopted March 6, 2026, enhancing change-in-control and good faith provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107054,"accession_number":"0001672688-26-000003","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci to Present Business Update at 44th Annual J.P. Morgan Healthcare Conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Absci will present a business update at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.","The presentation slides are filed as Exhibit 99.1 to this Form 8-K.","The slides are available in the 'Events and Presentations' section of Absci's investor relations website at investors.absci.com.","The Form 8-K was signed by CEO Sean McClain on January 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123395,"accession_number":"0001672688-25-000082","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.","Accelerated initiation of Phase 1/2a trial for ABS-201 in androgenetic alopecia to December 2025.","Expanding ABS-201 strategy to endometriosis, targeting Phase 2 start in Q4 2026 and proof-of-concept in H2 2027.","Cash, cash equivalents, and marketable securities totaled $152.5 million as of Sept 30, 2025, funding operations into H1 2028.","Net loss was $28.7 million for Q3 2025, compared to $27.4 million in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":2150000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123394,"accession_number":"0001672688-25-000076","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-11-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Absci resolves Totient merger milestone payments; receives $8.7M, pays $7.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Executed Letter Agreement with SBGH to distribute $16.3M escrow funds from 2021 Totient merger.","Absci receives $8.7M of Milestone Consideration; former Totient stockholders get $7.6M.","Agreement fully satisfies all milestone payment obligations under the Merger Agreement.","Escrow Agreement will terminate after disbursement within 5 business days.","Parties enter mutual release; no further payments owed by Absci."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140059,"accession_number":"0001628280-25-039878","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).","Raised $64M ($50M public offering + $14M ATM) in July 2025; cash+investments $117.5M at June 30; runway into H1 2028.","Expanded Almirall collaboration: second target elected for dermatology; up to $650M in potential milestones across two programs.","ABS-101 Phase 1 interim data expected H2 2025; ABS-201 on track for Phase 1/2a start early 2026 with efficacy readout H2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1772000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140056,"accession_number":"0001628280-25-039959","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K/A","filed_at":"2025-08-12T23:59:59+00:00","items":["9.01","2.02","8.01"],"status":"ready","headline":"Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.","Cash, equivalents, and ST investments $117.5M at June 30; raised ~$64M in July, extending runway into H1 2028.","Expanded Almirall AI drug discovery collaboration: second target elected, potential up to $650M in milestones across two programs.","ABS-101 (anti-TL1A) Phase 1 interim readout expected H2 2025; ABS-201 (anti-PRLR) Phase 1/2a start early 2026.","AMD strategic collaboration ongoing with $20M equity investment in Jan 2025; platform scaling using AMD Instinct accelerators."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":1772000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140058,"accession_number":"0001193125-25-165466","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-07-25T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Absci prices $50M public offering of 16.67M shares at $3.00 per share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16,670,000 shares at $3.00 per share; gross proceeds ~$50M.","Net proceeds estimated at ~$46.7M (or ~$53.7M if underwriters' option exercised in full).","Proceeds to fund internal programs, Integrated Drug Creation platform, and general corporate purposes.","Underwriters: Morgan Stanley, J.P. Morgan, Jefferies, TD Securities; expected close July 28, 2025.","Offer made under effective shelf registration statement on Form S-3 (File No. 333-267043)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140057,"accession_number":"0001628280-25-034544","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-07-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Absci appoints Mary Szela to Board effective July 7, 2025; grants 178,400 share option","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mary Szela appointed as Class III director; board expanded from six to seven members.","Receives initial option grant for 178,400 shares at closing price on grant date, vesting monthly over three years.","Will receive $40,000 annual cash retainer under Non-Employee Director Compensation Policy.","Szela currently serves as CEO, President and Director of Trisalus Life Sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157706,"accession_number":"0001628280-25-030953","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Absci stockholders elect van Houten and McGinnis to board, ratify EY as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Frans van Houten elected with 51.4M votes for, 15.7M withheld, 26.1M broker non-votes.","Karen McGinnis elected with 66.6M votes for, 0.55M withheld, same broker non-votes.","Ernst & Young ratified as auditor for FY 2025 with 92.8M for, 211k against, 208k abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157705,"accession_number":"0001628280-25-025075","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.","ABS-201 NHP data show extended half-life and >90% subcutaneous bioavailability; Phase 1 start targeted early 2026.","Q1 2025 revenue $1.2M (up from $0.9M YoY); net loss $26.3M vs $22.0M; R&D spending rose to $16.4M.","Cash, equivalents, and short-term investments of $134.0M sufficient to fund operations into first half of 2027.","Company expects to sign one or more new partnerships, including with a large pharma, in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":1179000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157704,"accession_number":"0001628280-25-020260","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Absci director Amrit Nagpal resigns from board effective April 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amrit Nagpal resigned from Absci's Board of Directors and all committees effective April 25, 2025.","Resignation not due to any disagreement with the Company on operations, policies, or practices.","No replacement for the vacant board seat has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176073,"accession_number":"0001628280-25-013455","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-03-18T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.","Cash & investments $112.4M; sufficient into H1 2027; gross cash burn ~$72M in FY2024.","ABS-101 anti-TL1A to enter Phase 1 in H1 2025; interim data expected H2 2025.","AMD strategic collaboration includes $20M equity investment; AI drug discovery workloads.","Expects to sign one or more drug creation partnerships in 2025, including with Large Pharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176072,"accession_number":"0001628280-25-001612","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci announces J.P. Morgan Healthcare Conference presentation; slides contain no new business data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation at 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025.","Exhibit 99.1 is only a title slide and disclaimer; no financial or operational updates disclosed.","No changes to guidance, pipeline, or financial position provided in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192986,"accession_number":"0001628280-24-046856","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q3 revenue $1.7M, net loss $27.4M; achieves AstraZeneca milestone, lowers 2024 cash burn guidance to ~$75M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.","First milestone achieved under AstraZeneca AI antibody collaboration; entered Twist Bioscience partnership for novel antibody design.","Gross cash use expected ~$75M for FY2024, below prior guidance of ~$80M; cash runway into first half 2027.","ABS-101 on track for Phase 1 initiation H1 2025 with interim data H2 2025; ABS-201 candidate selection expected H2 2024.","R&D expenses $18.0M (up from $11.0M) driven by IND-enabling studies for ABS-101; SG&A $9.3M (down from $9.5M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.68,"consensus_revenue_estimate":null,"consensus_revenue_actual":3869000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209360,"accession_number":"0001628280-24-039225","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-09-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.","AstraZeneca elected to advance sequences into AI-lead optimization phase.","Collaboration combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.","Goal: accelerate discovery of a potential new cancer treatment candidate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209359,"accession_number":"0001628280-24-037183","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).","Cash, cash equivalents and short-term investments $145.2M; expects runway into H1 2027.","ABS-101 NHP data: 2-3x extended half-life vs clinical anti-TL1A antibodies; 200 mg/mL formulation supports subcutaneous.","Entered collaboration with Memorial Sloan Kettering to co-develop up to 6 novel oncology therapeutics using generative AI.","Anticipates Phase 1 start for ABS-101 in early 2025; interim data readout expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.44,"consensus_revenue_estimate":null,"consensus_revenue_actual":2168000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227355,"accession_number":"0001628280-24-028285","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Absci stockholders elect three Class III directors and ratify EY as auditor at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Sean McClain, Amrit Nagpal, and Joseph Sirosh elected Class III directors for terms until 2027 annual meeting.","McClain received 65,972,631 votes for, 311,416 withhold; Nagpal 52,937,845 for, 13,346,202 withhold.","Sirosh received 66,155,521 for, 128,526 withhold; broker non-votes 27,170,637 on each director.","Ratification of Ernst & Young as independent auditor for FY 2024 approved with 93,309,150 for, 29,588 against, 115,946 abstain.","No other matters were submitted to or voted on at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227354,"accession_number":"0001628280-24-023060","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.","Cash, equivalents & short-term investments $161.5M as of Mar 31, 2024, up from $97.7M Dec 31, 2023; includes $86.4M gross from March offering.","IND-enabling studies initiated for ABS-101 (anti-TL1A antibody) in Feb 2024; expects Phase 1 start early 2025, interim data H2 2025.","Anticipates selecting development candidate for ABS-201 (dermatology) in H2 2024; ABS-301 (immuno-oncology) advancing.","Expects to sign at least four drug creation partnerships in 2024; cash runway into H1 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":898000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246226,"accession_number":"0001628280-24-012365","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.","Initiated IND-enabling for ABS-101 (anti-TL1A); IND expected Q1 2025.","Signed AstraZeneca collaboration for up to $247M in milestones plus royalties.","Raised $86.4M in common stock offering; cash $97.7M at Dec 31; runway into H1 2027.","Appointed Sir Menelas Pangalos to Board and co-chair of Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246225,"accession_number":"0001193125-24-050659","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Absci prices $75.2M public offering of 16.7M shares at $4.50; net proceeds $70.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 16.7M shares at $4.50/share; gross proceeds ~$75.2M; net proceeds ~$70.2M.","Underwriters granted 30-day option to purchase up to 2.505M additional shares.","Net proceeds to fund internal asset programs, Integrated Drug Creation platform, AI/wet-lab tech, and working capital.","Cash runway extended into first half of 2027; offering expected to close March 1, 2024.","Joint book-running managers: Morgan Stanley and TD Cowen."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246224,"accession_number":"0001193125-24-048027","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","8.01"],"status":"ready","headline":"Absci reports prelim FY2023 revenue $5.7M, cash $97.7M; proposes public offering","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary Q4 revenue ~$0.3M, FY revenue ~$5.7M; operating expenses $120-122M incl $21.3M goodwill impairment.","Unrestricted cash/short-term investments $97.7M as of Dec 31, 2023.","Filed preliminary prospectus for underwritten public offering of common stock (undisclosed size).","16 Active Programs with partners including AstraZeneca, Almirall, Merck; ABS-101 IND submission planned Q1 2025.","ABS-101 IND-enabling studies started Feb 2024; Phase 1 potentially H1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246223,"accession_number":"0001628280-24-000763","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci announces business update at J.P. Morgan Healthcare Conference; slides filed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed 8-K on Jan 8, 2024, referencing presentation slides as Exhibit 99.1.","Presentation slides provided contain only cover and legal disclaimers; no specific financial or operational updates included in the excerpt.","Conference presentation scheduled for 42nd Annual J.P. Morgan Healthcare Conference; details absent from filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263665,"accession_number":"0001628280-23-042078","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci announces strategic R&D partnership with PrecisionLife to develop AI-enabled drug pipeline","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Partnership combines Absci's generative AI antibody design with PrecisionLife's disease biology to develop up to five drug targets.","With this partnership, Absci has signed ten new Active Programs in 2023, achieving its full-year outlook.","Collaboration aims to create a shared pipeline of novel biotherapeutics for chronic diseases with unmet medical needs.","Absci and PrecisionLife will jointly evaluate options to advance programs and share in potential value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263664,"accession_number":"0001628280-23-040988","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-12-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Absci appoints Sir Menelas Pangalos (AstraZeneca EVP) to Board, effective Jan 1, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size fixed at 7 directors; Pangalos appointed as Class II director until 2026 annual meeting.","Initial option grant to purchase 106,200 shares, vesting monthly over 3 years from Grant Date.","Annual cash retainer of $47,500 for Board and Compensation Committee service.","Sir Pangalos currently serves as Executive Vice-President, R&D BioPharmaceuticals at AstraZeneca."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263663,"accession_number":"0001628280-23-040546","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Absci announces up to $247M AI antibody collaboration with AstraZeneca for oncology target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Absci to apply its generative AI antibody platform to design an oncology candidate for AstraZeneca.","Total deal consideration up to $247M, including upfront, R&D funding, milestones, plus royalties on sales.","Agreement combines Absci's Integrated Drug Creation platform with AstraZeneca's oncology expertise.","Platform aims to reduce drug design-validation cycle to ~6 weeks and expand target universe to GPCRs, ion channels.","Collaboration follows Absci's recent publication on 'zero-shot' generative AI model for de novo antibody design."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263662,"accession_number":"0001628280-23-038977","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Absci partners with Almirall (up to $664M deal) and reports Q3 net loss of $22M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered AI drug partnership with Almirall for dermatology; up to $664M in milestones plus royalties for two programs.","Q3 revenue fell to $0.7M from $2.4M YoY; net loss narrowed to $22.0M from $27.3M.","Unveiled four wholly-owned AI drug assets (cytokine biology); first IND filing expected early 2025.","Cash, equivalents, and short-term investments $113.5M; cash runway into late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280886,"accession_number":"0001628280-23-031311","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-09-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Absci cuts workforce 15% (30 employees), lowers 2023 cash burn guidance to ~$80M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Global workforce reduced ~15% (30 employees) to focus on internal drug pipeline and AI platform.","2023 gross cash use expected ~$80M, down from prior ~$90M; cash runway extended to late 2025.","No impact expected on ability to execute current/projected partner programs.","Organizational realignment driven by AI and wet lab integration efficiencies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280885,"accession_number":"0001628280-23-029853","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-08-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Sarah Korman to step down as Chief Legal Officer and interim Chief Business Officer of Absci Corp","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Mutual separation; effective September 15, 2023, with consulting period through October 15, 2023.","Entitled to 9 months severance, COBRA reimbursement, and prorated 2023 bonus of $97,139.","Stock options will vest monthly from March 1, 2023 instead of one-year cliff; continued vesting through consulting period.","No disagreement cited; company expresses gratitude for her service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280884,"accession_number":"0001628280-23-029198","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Absci appoints new CFO; Q2 revenue up but net loss widens on $21.3M goodwill impairment","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zach Jonasson, Ph.D. named CFO and CBO effective Aug 31, 2023, replacing retiring CFO Greg Schiffman.","Q2 revenue $3.4M vs $1.0M YoY; net loss $41.7M (incl. $21.3M goodwill impairment) vs $28.7M.","Cash and equivalents $124.6M; expects cash runway into late 2025.","Entered partnership with a Google Ventures-backed biotech; HIV vaccine collab with Caltech and Gates Foundation; completed Merck enzyme programs.","Expects at least 10 new Active Programs in 2023; gross cash use projected ~$90M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299541,"accession_number":"0001628280-23-022479","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-06-16T23:59:59+00:00","items":["1.01","5.03","5.07","9.01"],"status":"ready","headline":"Absci enters into $100M at-the-market equity offering with Cowen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ATM program allows Absci to sell up to $100M of common stock through Cowen as sales agent.","Cowen receives up to 3.0% commission on gross proceeds; no minimum sales required.","Stockholders elected Daniel Rabinovitsj as Class II director at June 14, 2023 annual meeting.","Annual meeting also approved officer liability limitation charter amendment and ratified Ernst & Young as auditor for FY2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299540,"accession_number":"0001628280-23-021102","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Absci appoints former Philips CEO Frans van Houten to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Frans van Houten appointed to Absci's Board effective June 2, 2023; Board size increased to 8 directors.","Van Houten will serve as Class I director until 2025 annual meeting, and join Audit and Nominating Committees.","Received initial option grant for 106,200 shares at $1.88 per share, vesting over three years.","Annual cash retainer of $55,000 for Board, Audit Committee, and Nominating Committee service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299539,"accession_number":"0001628280-23-018159","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q1 2023: Net loss $23.4M; cash $144.3M; zero-shot AI breakthrough; new partnerships","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $1.3M (up from $0.8M YoY); net loss narrowed to $23.4M from $29.5M.","Cash and investments $144.3M at March 31, 2023; runway into late 2025.","Achieved first zero-shot generative AI design of de novo therapeutic antibodies; hit rate 5-30x above baselines.","Partnered with Oxford Kennedy Institute (immune diseases) and Aster Insights (oncology) to apply AI platform.","Guidance: at least 10 new Active Programs in 2023; gross cash use ~$90M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.26,"consensus_revenue_estimate":null,"consensus_revenue_actual":1269000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319678,"accession_number":"0001628280-23-009897","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q4 2022 net loss $19.5M; full-year loss $104.9M; cash $164.4M; 10 new Active Programs in 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 revenue $1.6M, net loss $19.5M vs $25.2M loss in Q4 2021.","Full-year 2022 revenue $5.7M, net loss $104.9M vs $101.0M loss in 2021.","Cash, equivalents, and short-term investments $164.4M as of Dec 31, 2022, down from $252.6M.","Achieved zero-shot generative AI creation of de novo antibodies; hit rate 5-30x greater than baselines.","2023 outlook: at least 10 new Active Programs; gross cash use ~$90M, below prior year $105M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319677,"accession_number":"0001628280-23-007484","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2023-03-10T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Absci confirms no cash or securities at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Absci Corporation states it does not hold any deposits or securities at Silicon Valley Bank.","Disclosure made on March 10, 2023, following SVB's collapse.","No financial exposure to SVB, eliminating counterparty risk for investors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337885,"accession_number":"0001628280-22-032103","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Absci amends bylaws to align with universal proxy rules and DGCL changes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved amended bylaws effective December 15, 2022, adopting universal proxy card rules and recent DGCL updates.","Advance notice provisions revised: additional disclosures required from proposing stockholders and nominees.","Stockholder meetings may be held via remote communications; chair may set additional attendance procedures.","Votes for disqualified or withdrawn director nominees will be treated as abstentions.","Stockholders soliciting proxies must use a proxy card color other than white."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337884,"accession_number":"0001628280-22-029091","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q3 revenue $2.4M; cash burn guidance improved to ~$105M for 2022","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and short-term investments $181.3M at Sep 30, down from $206.0M at Jun 30; operating cash use $19.0M in Q3.","Q3 revenue $2.4M vs $1.5M YoY, driven by Merck collaboration milestone and nsAA technology progress.","R&D expense $15.5M (+45% YoY); SG&A $11.4M; includes $2.7M severance charges.","Exceeded 2022 Active Program guidance: 10 signed YTD vs 8 target; total Active Programs now 17.","Appointed Andreas Busch as Chief Innovation Officer and Dan Rabinovitsj to Board; cash runway into late 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":4190000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337883,"accession_number":"0001628280-22-027808","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Absci appoints Meta Connectivity VP Dan Rabinovitsj to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dan Rabinovitsj, Meta VP of Connectivity, appointed to Absci Board effective Nov 1, 2022, as Class II director.","He will serve on the Audit Committee and Nominating and Corporate Governance Committee.","Received initial option grant for 57,400 shares at $3.10 exercise price, vesting over 3 years.","Also receives $55,000 annual cash retainer for Board and committee service.","Appointment follows Dr. Andreas Busch's move to Chief Innovation Officer; Rabinovitsj brings tech scaling expertise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337882,"accession_number":"0001628280-22-025942","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-10-04T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Absci appoints Andreas Busch as Chief Innovation Officer; CTO Matthew Weinstock transitions to consultant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Andreas Busch resigns from Board on Sept 30 to become Chief Innovation Officer effective Oct 4, 2022.","Former CTO Matthew Weinstock to serve as consultant after Oct 4; receives 12-month base salary severance, COBRA reimbursement, and $145,125 prorated bonus.","Dr. Busch brings R&D expertise from Sanofi, Bayer, Shire; led over 10 drugs to FDA approval.","As Chief Innovation Officer, Dr. Busch will lead R&D, technical operations, and internal/partner programs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355239,"accession_number":"0001628280-22-025252","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-09-20T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Absci CSO Nikhil Goel to depart effective Sept 20, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Nikhil Goel, Chief Strategy Officer, leaving Absci as of Sept 20, 2022.","No replacement or reason for departure disclosed in the filing.","Company ticker ABSI trades on Nasdaq Global Select Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355238,"accession_number":"0001628280-22-022329","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q2 net loss $28.7M, exceeds Active Program guidance, restructures to extend cash to late-2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $28.7M in Q2 2022, compared to $41.2M loss in Q2 2021.","Cash and equivalents $206.0M as of June 30, 2022, down from $252.6M at Dec 31, 2021; 2022 cash decrease expected ~$110M.","Signed ten new Active Programs year-to-date, exceeding full-year guidance of at least eight; total now 19.","Strategic reorganization reduces headcount and extends cash runway into late 2025; workforce reduction included.","Entered multi-program collaboration with undisclosed biotech for antibody-drug conjugates using Bionic technology."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":1821000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355237,"accession_number":"0001628280-22-018928","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-07-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Eli Casdin resigns from Absci board effective July 11, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eli Casdin resigned from Absci's Board of Directors effective July 11, 2022.","Resignation due to focus on number of public company boards and primary professional responsibilities at Casdin Capital.","Mr. Casdin's resignation is not due to any disagreement with the company on operations, policies, or practices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373366,"accession_number":"0001628280-22-016865","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Absci stockholders elect two Class I directors, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Zachariah Jonasson, Ph.D. elected with 74,363,420 votes for, 4,628,210 withheld.","Karen McGinnis elected with 72,462,138 votes for, 6,529,492 withheld.","Ratification of Ernst & Young as auditor approved: 83,774,882 for, 8,248 against, 2,601 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373365,"accession_number":"0001628280-22-013758","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Absci Q1 net loss $29.5M; cash $226M; signs Merck collaboration worth up to $610M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $29.5M in Q1 2022 vs $11.0M in Q1 2021; R&D expense $15.8M, SG&A $10.9M.","Cash and equivalents $226.0M as of March 31, 2022, sufficient to fund operations through end of 2024.","Entered Merck collaboration for Bionic Enzyme generation; potential $610M in upfront and milestones plus royalties.","Unveiled AI models for antibody affinity prediction and naturalness scoring; partnered with NVIDIA.","Reiterates guidance of at least 8 new Active Programs in 2022 (60% YoY growth); 3 signed year-to-date."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":819000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392098,"accession_number":"0001628280-22-006887","cik":1672688,"company_name":"Absci Corp","ticker":"ABSI","form_type":"8-K","filed_at":"2022-03-22T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Absci posts Q4 revenue $1.5M, net loss $25.2M; reveals AI antibody design breakthroughs, partners NVIDIA","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2021 revenue $1.5M, net loss $25.2M vs $4.9M YoY; FY2021 net loss $101.0M vs $14.4M.","Cash of $279.9M; expects ~$120M net cash burn in 2022 (incl. ~$10.5M restricted cash).","Announced ML models predicting antibody affinity across 4 orders of magnitude and naturalness scoring.","Formed research collaboration with NVIDIA to scale in-silico drug discovery on A100 GPUs.","Entered Merck collaboration for Bionic Enzyme; projected 8 active programs in 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":892462898.1732558,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-03-22T23:59:59+00:00|392098"}